EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Laboratorios Farmaceuticos Rovi EBITDA Margin % Related Terms
Laboratorios Farmaceuticos Rovi EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ROVI vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a EBITDA Margin % of 13.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 44% below median its historical median of 24.67. Over the past decade, Laboratorios Farmaceuticos Rovi's EBITDA Margin % has ranged from 9.71 to 34.42. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #160 out of 955 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Laboratorios Farmaceuticos Rovi's EBITDA Margin % too high?
Laboratorios Farmaceuticos Rovi's current EBITDA Margin % of 13.93% is 44% below median its 10-year median of 24.67. Over the past 10 years, this metric has ranged from a low of 9.71 to a high of 34.42. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Laboratorios Farmaceuticos Rovi's value of 13.93% is 12% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #160 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #160 out of 955 companies for EBITDA Margin %. This places Laboratorios Farmaceuticos Rovi in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Laboratorios Farmaceuticos Rovi's value of 13.93% is 12% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own EBITDA Margin % has ranged from 9.71 to 34.42 over the past decade. While the company's 10-year median is 24.67 vs. the industry median of 12.44, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EBITDA Margin % of 13.93% is 12% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EBITDA Margin % is 13.93%, which is 44% below median its own 10-year median of 24.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €59.25 — trading 16.3% above its estimated fair value. The current EBITDA Margin % is 13.93%, which is 44% below median its 10-year median of 24.67 and 12% above the Drug Manufacturers industry median of 12.44. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current EBITDA Margin % is 13.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €59.25 is trading 16.3% above its estimated GF Value™ of €50.93.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
EBITDA Margin %: 13.93% (44% below median its 10-year median of 24.67)
GF Value™: €50.93 vs. price of €59.25 (16.3% above fair value)
Industry Position: 12% above the Drug Manufacturers median (#160 of 955)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score
Get the complete analysis for XMAD:ROVI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
